Gujarat Themis Biosyn Limited (506879) Fair Value & Analysis
Other · IN · Market cap ₹3.7B
Fair value as of: Jul 4, 2026
From 16 valuation models · updated today
Share price −3.8% over the past month.
Price vs Fair Value (12 months)
12‑month range ₹227.45 – ₹472.70 · fair‑value band ₹344.61 – ₹646.27 · the ₹386.30 price screens below the ₹495.44 fair value. As of Jul 4, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Gujarat Themis Biosyn Limited (506879) currently trades at ₹386.30, while our model-based Fair Value estimate is ₹495.44 — implying the stock looks roughly 28.3% undervalued today. We read business quality at 51/100 (solid quality), in the Other sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.
Over the trailing twelve months, Gujarat Themis Biosyn Limited generated revenue of ₹891M at a net margin of 31.3%. Revenue grew 33.8% year over year. Net debt stands at ₹1.6B. The stock trades on a trailing P/E of 11.3. Fundamentals as of Jul 4, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 4, 2026. TTM = trailing twelve months.
About the company
Gujarat Themis Biosyn Limited manufactures and sells bulk drugs on job work basis in India. Its products include Rifamycin-S, an intermediate for the treatment of tuberculosis; and Lovastatin. Gujarat Themis Biosyn Limited was incorporated in 1981 and is based in Vapi, India.
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Gujarat Themis Biosyn Limited reported revenue of ₹1.7B in FY2026 versus ₹1.1B in FY2022, a compound +9.6%/yr. Reported net income was ₹467M in FY2026, compounding +1.7%/yr from FY2022.
Is 506879 fairly valued? → Check now
Similar stocks
6 more Other stocks, each showing price versus our Fair Value estimate (as of Jul 4, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| There MOH | €521.90 | €269.92 | -48% |
| Sony Corporation SON1 | €17.58 | €37.56 | +114% |
| Federal Home Loan Mortgage Corporation FREJO | $16.84 | $64.93 | +286% |
| 533278 533278 | ₹438.60 | ₹720.31 | +64% |
| Nestl?? India Limited 500790 | ₹1,459 | ₹279.60 | -81% |
| 540376 540376 | ₹3,993 | ₹1,806 | -55% |
Explore undervalued stocks
Frequently asked questions
Is Gujarat Themis Biosyn Limited (506879) undervalued?
What is the fair value of 506879?
What is the quality score of 506879?
What is the revenue of Gujarat Themis Biosyn Limited (506879)?
What is the net profit margin of 506879?
Does Gujarat Themis Biosyn Limited pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.